Mangoceuticals to Merge with Nuclear Startup Nuclea Energy, Leaving Existing Shareholders with Just 4%
MGRX has more than doubled off its 52-week low of $0.162 on light trading volume (0.2× avg).
Summary
Mangoceuticals is being reverse-merged into nuclear startup Nuclea Energy, leaving existing shareholders with just 4% of the combined company. The deal includes a $15 million PIPE, a CEO exit package, and governance changes to secure approval.
Key Events · M&A and Partnerships · MGRX
-
Reverse Merger with Nuclea Energy
Mangoceuticals entered into a Business Combination Agreement with Nuclea Energy Inc., a developer of lead-cooled nuclear microreactors. Nuclea shareholders will receive exchangeable shares, resulting in approximately 96% ownership of the combined company, with existing Mango shareholders holding just 4%.
-
$15 Million PIPE Financing Condition
Closing is contingent on a private investment in public equity (PIPE) of at least $15 million, to be funded into escrow and released at closing. Proceeds will cover $1.5 million in Mango liabilities, $1.5 million CEO severance, and provide working capital for Nuclea.
-
CEO Exit Package
CEO Jacob Cohen will receive $1.5 million cash severance, 2 million fully vested shares (issued immediately), and a $10 million cashless warrant for Mango & Peaches Corp. stock upon deal completion. He will transition to President as a consultant.
-
Governance Changes to Secure Approval
The board amended bylaws to reduce the shareholder meeting quorum from a majority to one-third of voting power, making it easier to achieve the required stockholder vote. The company also issued 400,000 fully vested shares to directors and the CFO.
Analysis · MGRX · Industrial Applications And Services
A struggling men's wellness company with a going concern warning and a sub-$10 million market cap, Mangoceuticals is being acquired in a reverse merger by Nuclea Energy, a private Canadian nuclear microreactor developer. Existing Mango shareholders will be diluted to approximately 4% ownership, while Nuclea shareholders will control 96% post-closing. The deal is contingent on a minimum $15 million PIPE financing — a lifeline for the cash-strapped company — and requires Nasdaq and shareholder approvals. CEO Jacob Cohen is exiting with a $1.5 million cash severance, 2 million shares, and a $10 million warrant. The board also lowered the shareholder meeting quorum to one-third, easing the path to approval. This is a complete transformation of the company's business and capital structure.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.5% of the 331 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.16 to $2.75. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.